Linking histological healing to quality of life: real-world insights into golimumab therapy in ulcerative colitis.

IF 2.2 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Current Medical Research and Opinion Pub Date : 2025-07-01 Epub Date: 2025-07-26 DOI:10.1080/03007995.2025.2535454
Rodrigo Galhardi Gasparini, Carlos Taxonera, Antônio José Tibúrcio Alves Júnior, Bianca Loyo Pona Schiavetti, Francisco Guilherme Cancela E Penna, Richard Borba Magalhães, Sandro da Costa Ferreira, Renata de Sá Brito Fróes, Carlos Henrique Marques Dos Santos, Cristina Flores, Bruno César da Silva, Rogério Serafim Parra, Alexandre Venâncio, Hélio Rzetelna, Carlos Frederico Pereira Porto Alegre Rosa, Adriana Ribas Andrade
{"title":"Linking histological healing to quality of life: real-world insights into golimumab therapy in ulcerative colitis.","authors":"Rodrigo Galhardi Gasparini, Carlos Taxonera, Antônio José Tibúrcio Alves Júnior, Bianca Loyo Pona Schiavetti, Francisco Guilherme Cancela E Penna, Richard Borba Magalhães, Sandro da Costa Ferreira, Renata de Sá Brito Fróes, Carlos Henrique Marques Dos Santos, Cristina Flores, Bruno César da Silva, Rogério Serafim Parra, Alexandre Venâncio, Hélio Rzetelna, Carlos Frederico Pereira Porto Alegre Rosa, Adriana Ribas Andrade","doi":"10.1080/03007995.2025.2535454","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Ulcerative colitis (UC) significantly impacts patients' quality of life (QoL). Therapeutic strategies have increasingly focused on achieving histological and endoscopic remission in addition to clinical outcomes and patient-reported measures. Real-world data on the effectiveness of golimumab to achieve histologic remission is scarce.</p><p><strong>Methods: </strong>This was a multicenter, cohort study including 73 patients with moderate-to-severe UC treated with golimumab across Brazilian centers. Outcomes were assessed at weeks 24 and 54 and included histological remission (Nancy histological index [NHI]), endoscopic remission (Mayo endoscopic subscore [MES]), inflammatory biomarkers (CRP and fecal calprotectin), and QoL (IBDQ-36). Correlations between histological scores with endoscopic outcomes and QoL were analyzed using Spearman test.</p><p><strong>Results: </strong>At week 24, 32.4% of patients achieved complete histological remission (NHI grade 0), and 80.8% achieved endoscopic remission (MES 0 or 1). At week 54, 55.2% of patients had histological remission and 84.4% of patients achieved endoscopic remission. Mean CRP levels decreased from 13.16 mg/dL at baseline to 1.35 mg/dL at week 54 (<i>p</i> < 0.001), and mean calprotectin decreased from 2113.2 to 106.9 mcg/g (<i>p</i> < 0.001). QoL significantly improved, with IBDQ-36 scores increasing from 121.5 at baseline to 182.1 at week 24 and 194.2 at week 54 (<i>p</i> = 0.002). Significant correlations were observed between NHI with MES and IBDQ-36 at week 24.</p><p><strong>Conclusion: </strong>Golimumab has achieved sustained efficacy in the induction of histological and endoscopic remission and improvement in QoL in patients with moderate-to-severe UC in a real-world setting. These results support the use of golimumab as an effective, patient-centered therapeutic option, particularly when multidimensional disease control is the goal.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1219-1226"},"PeriodicalIF":2.2000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Medical Research and Opinion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/03007995.2025.2535454","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/26 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Ulcerative colitis (UC) significantly impacts patients' quality of life (QoL). Therapeutic strategies have increasingly focused on achieving histological and endoscopic remission in addition to clinical outcomes and patient-reported measures. Real-world data on the effectiveness of golimumab to achieve histologic remission is scarce.

Methods: This was a multicenter, cohort study including 73 patients with moderate-to-severe UC treated with golimumab across Brazilian centers. Outcomes were assessed at weeks 24 and 54 and included histological remission (Nancy histological index [NHI]), endoscopic remission (Mayo endoscopic subscore [MES]), inflammatory biomarkers (CRP and fecal calprotectin), and QoL (IBDQ-36). Correlations between histological scores with endoscopic outcomes and QoL were analyzed using Spearman test.

Results: At week 24, 32.4% of patients achieved complete histological remission (NHI grade 0), and 80.8% achieved endoscopic remission (MES 0 or 1). At week 54, 55.2% of patients had histological remission and 84.4% of patients achieved endoscopic remission. Mean CRP levels decreased from 13.16 mg/dL at baseline to 1.35 mg/dL at week 54 (p < 0.001), and mean calprotectin decreased from 2113.2 to 106.9 mcg/g (p < 0.001). QoL significantly improved, with IBDQ-36 scores increasing from 121.5 at baseline to 182.1 at week 24 and 194.2 at week 54 (p = 0.002). Significant correlations were observed between NHI with MES and IBDQ-36 at week 24.

Conclusion: Golimumab has achieved sustained efficacy in the induction of histological and endoscopic remission and improvement in QoL in patients with moderate-to-severe UC in a real-world setting. These results support the use of golimumab as an effective, patient-centered therapeutic option, particularly when multidimensional disease control is the goal.

将组织学愈合与生活质量联系起来:对溃疡性结肠炎戈利姆单抗治疗的真实世界见解。
背景:溃疡性结肠炎(UC)显著影响患者的生活质量(QoL)。除了临床结果和患者报告的措施外,治疗策略越来越侧重于实现组织学和内窥镜缓解。关于戈利姆单抗实现组织学缓解的有效性的实际数据很少。方法:这是一项多中心队列研究,包括巴西各中心接受golimumab治疗的73例中重度UC患者。结果在第24周和第54周进行评估,包括组织学缓解(Nancy组织学指数[NHI])、内镜缓解(Mayo内镜亚评分[MES])、炎症生物标志物(CRP和粪便钙保护蛋白)和生活质量(IBDQ-36)。采用Spearman检验分析组织学评分与内镜预后和生活质量的相关性。结果:在第24周,32.4%的患者达到完全组织学缓解(NHI分级0),80.8%的患者达到内镜缓解(MES 0或1)。在第54周,55.2%的患者有组织学缓解,84.4%的患者有内窥镜缓解。平均CRP水平从基线时的13.16 mg/dL降至第54周时的1.35 mg/dL (p)。结论:在现实环境中,Golimumab在诱导组织学和内镜下缓解以及改善中重度UC患者的生活质量方面取得了持续的疗效。这些结果支持使用golimumab作为一种有效的、以患者为中心的治疗选择,特别是当以多维疾病控制为目标时。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current Medical Research and Opinion
Current Medical Research and Opinion 医学-医学:内科
CiteScore
4.40
自引率
4.30%
发文量
247
审稿时长
3-8 weeks
期刊介绍: Current Medical Research and Opinion is a MEDLINE-indexed, peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, Phase II-IV studies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged. Preclinical, Phase I, pharmacoeconomic, outcomes and quality of life studies may also be considered if there is clear clinical relevance
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信